share_log

科濟藥業-B：自願公告 - 賽愷澤、CT071和CT0590的數據將於2024年ASH年會上展示

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - TO PRESENT ZEVORCABTAGENE AUTOLEUCEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS

HKEX ·  Oct 16 17:00

Summary by Moomoo AI

科濟藥業-B（股份代號：2171）自願公告，將於2024年第66屆美國血液學會（ASH）年會上展示旗下三款CAR-T細胞療法產品的臨床數據。這些產品包括賽愷澤®（CT053）、CT071和CT0590，分別針對多發性骨髓瘤（MM）和漿細胞白血病（PCL）。賽愷澤®已於2024年2月23日獲國家藥品監督管理局批准上市，用於治療經過至少3線治療後進展的復發或難治性MM成人患者。CT071和CT0590目前正在中國進行臨床試驗。科濟藥業專注於創新CAR-T細胞療法，旨在治療血液惡性腫瘤和實體瘤，並已建立從靶點發現到商業規模生產的研發平台。摘要和進一步信息將於2024年11月5日後公佈。
科濟藥業-B（股份代號：2171）自願公告，將於2024年第66屆美國血液學會（ASH）年會上展示旗下三款CAR-T細胞療法產品的臨床數據。這些產品包括賽愷澤®（CT053）、CT071和CT0590，分別針對多發性骨髓瘤（MM）和漿細胞白血病（PCL）。賽愷澤®已於2024年2月23日獲國家藥品監督管理局批准上市，用於治療經過至少3線治療後進展的復發或難治性MM成人患者。CT071和CT0590目前正在中國進行臨床試驗。科濟藥業專注於創新CAR-T細胞療法，旨在治療血液惡性腫瘤和實體瘤，並已建立從靶點發現到商業規模生產的研發平台。摘要和進一步信息將於2024年11月5日後公佈。
Cancer pharmaceutical-B (stock code: 2171) voluntarily announced that it will present clinical data of its three CAR-T cell therapy products at the 66th American Society of Hematology (ASH) Annual Meeting in 2024. These products include Caikez® (CT053), CT071, and CT0590, targeting multiple myeloma (MM) and plasma cell leukemia (PCL) respectively. Caikez® was approved for marketing by the National Medical Products Administration on February 23, 2024, for the treatment of relapsed or refractory MM in adult patients who have progressed after at least 3 lines of treatment. CT071 and CT0590 are currently undergoing clinical trials in china. Sci-tech pharmaceutical is dedicated to innovative CAR-T cell therapy aimed at treating hematologic malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production. Summary and further information will be announced after November 5, 2024.
Cancer pharmaceutical-B (stock code: 2171) voluntarily announced that it will present clinical data of its three CAR-T cell therapy products at the 66th American Society of Hematology (ASH) Annual Meeting in 2024. These products include Caikez® (CT053), CT071, and CT0590, targeting multiple myeloma (MM) and plasma cell leukemia (PCL) respectively. Caikez® was approved for marketing by the National Medical Products Administration on February 23, 2024, for the treatment of relapsed or refractory MM in adult patients who have progressed after at least 3 lines of treatment. CT071 and CT0590 are currently undergoing clinical trials in china. Sci-tech pharmaceutical is dedicated to innovative CAR-T cell therapy aimed at treating hematologic malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production. Summary and further information will be announced after November 5, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated